-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels BiotechnologyInnoModels Biotechnology: CDX Model - A Unique Tool to Reveal Tumor Properties
Author:
InnoModels
Release time:
2024-04-02
With the deepening of biomedical research, the establishment of tumor models is of great significance in understanding the mechanisms of tumor occurrence, development and treatment. As an important tumor model, the CDX model of InnoModels Biotechnology plays an important role in tumor research with its unique characteristics. In this paper, we will introduce the unique features of the CDX model of InnoModels Biotechnology in detail.
1、Tumor heterogeneity is maintained
By transplanting artificially purified and multigenerationally cultured tumor cell lines into mice, the CDX model of InnoModels Biotechnology can maintain the heterogeneity of tumors. This heterogeneity reflects the genetic and phenotypic differences between different cells within the tumor, which helps researchers understand the biological characteristics of the tumor more deeply.
2. Stability of biological properties
The CDX model of InnoModels Biotechnology uses tumor cell lines that have been passed on many times, and these cell lines undergo strict quality control to ensure the stability of biological characteristics. This stability makes the CDX model more reliable in simulating tumor growth, invasion and metastasis.

3. Highly similar to human tumors
By simulating the growth environment and biological process of human tumors, the CDX model of Transmooker Biologicals has a high degree of similarity with human tumors in terms of gene expression, protein expression, and signaling pathways, etc. This makes the CDX model an ideal tool for researching tumors. This makes the CDX model an important tool for the study of tumorigenesis, development, therapeutic mechanism and drug screening.
4. High-throughput drug screening
The CDX model has the ability of high-throughput drug screening. By implanting tumor cell lines in mice, the inhibitory effect of drugs on tumor growth can be quickly assessed, providing an important basis for drug development. In addition, the model can also be used to study the drug resistance mechanism and the mechanism of tumor recurrence, providing new ideas and methods for clinical treatment.
5、Development of personalized treatment strategy
The InnoModels CDX model can be used to simulate the tumor characteristics of patients so as to formulate personalized treatment strategies. Through gene sequencing and phenotypic analysis of the patient's tumor tissues, we can screen out the suitable therapeutic drugs and solutions for the patient, and improve the therapeutic effect and survival rate of the patient.
In conclusion, the InnoModels Biotechnology CDX model has become an important tool in the field of tumor research due to its unique features of tumor heterogeneity retention, stability of biological properties, high similarity to human tumors, high-throughput drug screening ability, and the development of personalized treatment strategies. With the continuous progress of technology and the expansion of application scope, CDX model will play an increasingly important role in basic tumor research and clinical treatment.
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd